+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Europe Molecular Diagnostics Market Size, Share & Trends Analysis Report by Product (Instruments, Reagents, Software), Technology (PCR, in Situ Hybridization, INAAT, Chips & Microarrays, Sequencing), Country, and Segment Forecasts, 2023-2030

  • PDF Icon

    Report

  • 65 Pages
  • November 2023
  • Region: Europe
  • Grand View Research
  • ID: 5914571
The Europe molecular diagnostics market size is expected to reach USD 7.4 billion by 2030 registering a CAGR of 2.7%, according to the report. Growing geriatric population and the increasing prevalence of neurological and cardiovascular disorders is expected to drive the growth of molecular diagnostics. Moreover, increasing demand for more efficient healthcare delivery to facilitate early diagnostics is further expected to boost market growth.

Rising awareness levels among individuals pertaining to the availability of effective molecular diagnostic tests to determine the presence of genetic disorders is expected to increase the client base for this industry, consequently leading to early diagnosis of disorders in the population.

In addition, with the demand for high levels of accuracy and cost effectiveness of diagnostic procedures, the existent technologies are continually undergoing progressive changes to develop improved and efficient testing tools. Presence of a number of established healthcare facilities coupled with the technological advancements facilitating and expediting accurate disease diagnosis are expected to serve this market as significant drivers fueling growth.

Europe Molecular Diagnostics Market Report Highlights

  • The reagents segment dominated the market in 2022 with a revenue share of more than 60% and is expected to grow at a significant CAGR over the forecast period.
  • The PCR segment accounted for the largest revenue share of over 75% in 2022, attributable largely to the increasing application of molecular diagnostics in the field of pharmacogenomics and the growing usage of multiplex PCR technologies.
  • The in situ hybridization (ISH) and sequencing segments are expected to grow at the fastest CAGR of 11.3% over the forecast period. ISH is a highly sensitive and specific technique that can be used to detect cancer at an early stage when it is most treatable.
  • The UK held a significant market revenue share in 2022 due to well-developed healthcare infrastructure, surging disposable income, and rising awareness levels among individuals for the early diagnosis of life-threatening diseases, including cancer and HIV.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Product
1.1.2. Technology
1.1.3. Country scope
1.1.4. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. Internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product outlook
2.2.2. Technology outlook
2.2.3. Country outlook
2.3. Competitive Insights
Chapter 3. Europe Molecular Diagnostics Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Europe Molecular Diagnostics Market Analysis Tools
3.4.1. Industry Analysis - Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
Chapter 4. Europe Molecular Diagnostics: Product Estimates & Trend Analysis
4.1. Europe Molecular Diagnostics Market: Key Takeaways
4.2. Europe Molecular Diagnostics Market: Movement & Market Share Analysis, 2022 & 2030
4.3. Instruments
4.3.1. Instruments market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. Reagents
4.4.1. Reagents market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. Software
4.5.1. Software market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Europe Molecular Diagnostics: Technology Estimates & Trend Analysis
5.1. Europe Molecular Diagnostics Market: Key Takeaways
5.2. Europe Molecular Diagnostics Market: Movement & Market Share Analysis, 2022 & 2030
5.3. Polymerase Chain Reaction (PCR)
5.3.1. PCR market estimates and forecasts, 2018 to 2030 (USD Million)
5.4. In Situ Hybridization
5.4.1. In situ hybridization market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. Isothermal Nucleic Acid Amplification Technology (INAAT)
5.5.1. INAAT market estimates and forecasts, 2018 to 2030 (USD Million)
5.6. Chips & Microarrays
5.6.1. Chips & microarrays market estimates and forecasts, 2018 to 2030 (USD Million)
5.7. Mass Spectrometry
5.7.1. Mass spectrometry market estimates and forecasts, 2018 to 2030 (USD Million)
5.8. Sequencing
5.8.1. Sequencing market estimates and forecasts, 2018 to 2030 (USD Million)
5.9. Transcription-mediated Amplification (TMA)
5.9.1. TMA market estimates and forecasts, 2018 to 2030 (USD Million)
5.10. Others
5.10.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Europe Molecular Diagnostics Market: Country Estimates & Trend Analysis
6.1. Country Outlook
6.2. Europe Molecular Diagnostics Market by Country: Key Takeaways
6.3. Europe
6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.3.2. UK
6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.3.3. Germany
6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.3.4. France
6.3.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.3.5. Spain
6.3.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.3.6. Italy
6.3.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.3.7. Belgium
6.3.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.3.8. Switzerland
6.3.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.3.9. Netherlands
6.3.9.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.3.10. Poland
6.3.10.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.3.11. Austria
6.3.11.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.3.12. Denmark
6.3.12.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.3.13. Sweden
6.3.13.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.3.14. Turkey
6.3.14.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.3.15. Norway
6.3.15.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Market Participant Categorization
7.2.1. Abbott Laboratories
7.2.1.1. Company overview
7.2.1.2. Financial performance
7.2.1.3. Product benchmarking
7.2.1.4. Strategic initiatives
7.2.2. Alere, Inc.
7.2.2.1. Company overview
7.2.2.2. Financial performance
7.2.2.3. Product benchmarking
7.2.2.4. Strategic initiatives
7.2.3. Bayer Healthcare
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. Becton, Dickinson and Company
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. bioMérieux
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. Bio-Rad Laboratories, Inc.
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. Cepheid
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives
7.2.8. Dako
7.2.8.1. Company overview
7.2.8.2. Financial performance
7.2.8.3. Product benchmarking
7.2.8.4. Strategic initiatives
7.2.9. Danaher Corporation
7.2.9.1. Company overview
7.2.9.2. Financial performance
7.2.9.3. Product benchmarking
7.2.9.4. Strategic initiatives
7.2.10. Hologic, Inc. (Gen Probe)
7.2.10.1. Company overview
7.2.10.2. Financial performance
7.2.10.3. Product benchmarking
7.2.10.4. Strategic initiatives
7.2.11. Johnson & Johnson
7.2.11.1. Company overview
7.2.11.2. Financial performance
7.2.11.3. Product benchmarking
7.2.11.4. Strategic initiatives
7.2.12. Novartis AG (Grifols)
7.2.12.1. Company overview
7.2.12.2. Financial performance
7.2.12.3. Product benchmarking
7.2.12.4. Strategic initiatives
7.2.13. Qiagen N.V.
7.2.13.1. Company overview
7.2.13.2. Financial performance
7.2.13.3. Product benchmarking
7.2.13.4. Strategic initiatives
7.2.14. Roche Diagnostics
7.2.14.1. Company overview
7.2.14.2. Financial performance
7.2.14.3. Product benchmarking
7.2.14.4. Strategic initiatives
7.2.15. Siemens Healthcare GmbH
7.2.15.1. Company overview
7.2.15.2. Financial performance
7.2.15.3. Product benchmarking
7.2.15.4. Strategic initiatives
7.2.16. Sysmex Corporation
7.2.16.1. Company overview
7.2.16.2. Financial performance
7.2.16.3. Product benchmarking
7.2.16.4. Strategic initiatives
List of Tables
Table 1 List of Abbreviations
Table 2 Europe molecular diagnostics market, by product, 2018 - 2030 (USD Million)
Table 3 Europe molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 4 Europe molecular diagnostics market, by country, 2018 - 2030 (USD Million)
Table 5 UK molecular diagnostics market, by product, 2018 - 2030 (USD Million)
Table 6 UK molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 7 Germany molecular diagnostics market, by product, 2018 - 2030 (USD Million)
Table 8 Germany molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 9 France molecular diagnostics market, by product, 2018 - 2030 (USD Million)
Table 10 France molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 11 Spain molecular diagnostics market, by product, 2018 - 2030 (USD Million)
Table 12 Spain molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 13 Italy molecular diagnostics market, by product, 2018 - 2030 (USD Million)
Table 14 Italy molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 15 Belgium molecular diagnostics market, by product, 2018 - 2030 (USD Million)
Table 16 Belgium molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 17 Switzerland molecular diagnostics market, by product, 2018 - 2030 (USD Million)
Table 18 Switzerland molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 19 Netherlands molecular diagnostics market, by product, 2018 - 2030 (USD Million)
Table 20 Netherlands molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 21 Poland molecular diagnostics market, by product, 2018 - 2030 (USD Million)
Table 22 Poland molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 23 Austria molecular diagnostics market, by product, 2018 - 2030 (USD Million)
Table 24 Austria molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 25 Denmark molecular diagnostics market, by product, 2018 - 2030 (USD Million)
Table 26 Denmark molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 27 Sweden molecular diagnostics market, by product, 2018 - 2030 (USD Million)
Table 28 Sweden molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 29 Turkey molecular diagnostics market, by product, 2018 - 2030 (USD Million)
Table 30 Turkey molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 31 Norway molecular diagnostics market, by product, 2018 - 2030 (USD Million)
Table 32 Norway molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 33 Rest of EU molecular diagnostics market, by product, 2018 - 2030 (USD Million)
Table 34 Rest of EU molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Europe molecular diagnostics: Market outlook
Fig. 9 Europe molecular diagnostics: Competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Industry value chain analysis
Fig. 14 Europe molecular diagnostics market driver impact
Fig. 15 Europe molecular diagnostics market restraint impact
Fig. 16 Europe molecular diagnostics market strategic initiatives analysis
Fig. 17 Europe molecular diagnostics market: Product movement analysis
Fig. 18 Europe molecular diagnostics market: Product outlook and key takeaways
Fig. 19 Instruments market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 20 Reagents market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 21 Software market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 22 Europe molecular diagnostics market: Technology movement analysis
Fig. 23 Europe molecular diagnostics market: Technology outlook and key takeaways
Fig. 24 PCR market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 25 In situ hybridization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 26 INAAT market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 27 Chips and microarrays market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 28 Mass spectrometry market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 29 Sequencing market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 30 TMA market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 31 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 32 Europe molecular diagnostics market: Country movement analysis
Fig. 33 Europe molecular diagnostics market: Country outlook and key takeaways
Fig. 34 UK market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 35 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 36 France market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 37 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 38 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 39 Belgium market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 40 Switzerland market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 41 Netherlands market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 42 Poland market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 43 Austria market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 44 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 45 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 46 Turkey market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 47 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 48 Rest of EU market estimates and forecasts, 2018 - 2030 (USD Million)

Companies Profiled

  • Abbott Laboratories
  • Alere, Inc.
  • Bayer Healthcare
  • Becton, Dickinson and Company
  • bioMérieux
  • Bio-Rad Laboratories, Inc.
  • Cepheid
  • Dako
  • Danaher Corporation
  • Hologic, Inc. (Gen Probe)
  • Johnson & Johnson
  • Novartis AG (Grifols)
  • Qiagen N.V.
  • Roche Diagnostics
  • Siemens Healthcare GmbH
  • Sysmex Corporation

Methodology

Loading
LOADING...